S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Energy traders: A rebound is coming
Retail sector resurgence: optimism grows for holiday momentum
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Energy traders: A rebound is coming
Retail sector resurgence: optimism grows for holiday momentum
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Energy traders: A rebound is coming
Retail sector resurgence: optimism grows for holiday momentum
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Energy traders: A rebound is coming
Retail sector resurgence: optimism grows for holiday momentum
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Chick-fil-A Is Hiring an 'Entertainment Producer'
All the trading advice you’ve ever received boils down to this (Ad)
Dell, Marvell Technology fall; Ulta Beauty, UiPath rise, Friday, 12/1/2023
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead

Kymera Therapeutics (KYMR) News Today

$20.77
+0.01 (+0.05%)
(As of 12/1/2023 ET)
Compare
Today's Range
$19.73
$20.97
50-Day Range
$10.97
$20.89
52-Week Range
$9.60
$39.85
Volume
364,797 shs
Average Volume
736,775 shs
Market Capitalization
$1.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.30
SourceHeadline
MarketBeat logoKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts
americanbankingnews.com - November 25 at 3:32 AM
markets.businessinsider.com logoAnalyst Expectations for Kymera Therapeutics's Future
markets.businessinsider.com - November 13 at 2:38 PM
finance.yahoo.com logoKymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
finance.yahoo.com - November 13 at 2:38 PM
seekingalpha.com logoKymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases
seekingalpha.com - November 12 at 2:27 AM
finance.yahoo.com logoBIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics Inc
finance.yahoo.com - November 7 at 1:25 PM
finance.yahoo.com logoKymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 5 at 5:53 PM
es-us.finanzas.yahoo.com logoKymera Therapeutics Inc (KYMR) Announces Q3 2023 Financial Results
es-us.finanzas.yahoo.com - November 4 at 10:13 PM
markets.businessinsider.com logoHC Wainwright & Co. Maintains Buy Rating for Kymera Therapeutics: Here's What You Need To Know
markets.businessinsider.com - November 3 at 3:57 PM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC) and Kymera Therapeutics (KYMR)
markets.businessinsider.com - November 3 at 9:48 AM
finance.yahoo.com logoKymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
finance.yahoo.com - November 2 at 8:35 AM
finance.yahoo.com logoKymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
finance.yahoo.com - November 2 at 8:35 AM
benzinga.com logoPreview: Kymera Therapeutics's Earnings
benzinga.com - November 1 at 2:47 PM
finance.yahoo.com logoKymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
finance.yahoo.com - October 27 at 7:45 AM
finance.yahoo.com logoWill Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Know
finance.yahoo.com - October 26 at 3:19 PM
finance.yahoo.com logoKymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
finance.yahoo.com - October 26 at 10:18 AM
finance.yahoo.com logoKymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
finance.yahoo.com - October 19 at 3:21 PM
finance.yahoo.com logoKymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
finance.yahoo.com - October 18 at 1:25 PM
finance.yahoo.com logoKymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
finance.yahoo.com - October 16 at 8:18 AM
finance.yahoo.com logoKymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?
finance.yahoo.com - October 4 at 8:46 AM
finance.yahoo.com logoWhy Shares of Kymera Therapeutics Jumped on Tuesday
finance.yahoo.com - October 3 at 8:44 PM
marketbeat.com logoHarbor Capital Advisors Inc. Buys 20,059 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)
marketbeat.com - September 19 at 6:38 AM
finance.yahoo.com logoKymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
finance.yahoo.com - September 18 at 9:22 AM
marketbeat.com logoKymera Therapeutics, Inc. (NASDAQ:KYMR) is Atlas Venture Life Science Advisors LLC's Largest Position
marketbeat.com - September 12 at 6:13 AM
marketbeat.com logoProfund Advisors LLC Makes New $1.15 Million Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
marketbeat.com - September 1 at 7:53 AM
finance.yahoo.com logoIndustry Analysts Just Upgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts By 19%
finance.yahoo.com - August 31 at 7:29 AM
msn.com logoMorgan Stanley Maintains Kymera Therapeutics (KYMR) Equal-Weight Recommendation
msn.com - August 30 at 9:23 AM
markets.businessinsider.com logoThe Latest Analyst Ratings for Kymera Therapeutics
markets.businessinsider.com - August 29 at 6:23 PM
finance.yahoo.com logoKymera Therapeutics to Participate in Upcoming September Investor Conferences
finance.yahoo.com - August 28 at 10:10 AM
msn.com logoKymera Therapeutics - Need More Developments Before Making This A Buy
msn.com - August 9 at 5:40 PM
marketbeat.com logoSG Americas Securities LLC Invests $260,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
marketbeat.com - August 9 at 4:35 AM
msn.com logoStifel Maintains Kymera Therapeutics (KYMR) Buy Recommendation
msn.com - August 8 at 1:21 PM
marketbeat.com logoKymera Therapeutics, Inc. (NASDAQ:KYMR) Position Trimmed by Barclays PLC
marketbeat.com - August 8 at 6:11 AM
markets.businessinsider.com logoTruist Financial Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
markets.businessinsider.com - August 7 at 2:55 AM
seekingalpha.com logoKymera Therapeutics: A Status Update
seekingalpha.com - August 6 at 7:21 AM
marketbeat.com logoKymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results
marketbeat.com - August 4 at 8:24 PM
markets.businessinsider.com logoH.C. Wainwright Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
markets.businessinsider.com - August 4 at 5:50 PM
msn.com logoHC Wainwright & Co. Reiterates Kymera Therapeutics (KYMR) Buy Recommendation
msn.com - August 4 at 5:50 PM
markets.businessinsider.com logoExpert Ratings for Kymera Therapeutics
markets.businessinsider.com - August 4 at 5:50 PM
marketbeat.com logoCredit Suisse Group Boosts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $37.00
marketbeat.com - August 4 at 11:26 AM
finance.yahoo.com logoKymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
finance.yahoo.com - August 3 at 8:37 AM
marketbeat.com logoKymera Therapeutics (KYMR) Set to Announce Quarterly Earnings on Thursday
marketbeat.com - July 28 at 10:17 AM
finance.yahoo.com logoKymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
finance.yahoo.com - July 27 at 10:56 AM
marketbeat.com logoRaymond James & Associates Has $679,000 Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
marketbeat.com - July 25 at 4:20 AM
marketbeat.com logoKymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Moderate Buy" by Analysts
marketbeat.com - July 23 at 4:36 AM
finance.yahoo.com logoCompanies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
finance.yahoo.com - July 9 at 10:20 AM
msn.com logoTruist Securities Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation
msn.com - July 1 at 12:21 PM
marketbeat.com logoKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of "Moderate Buy" from Analysts
marketbeat.com - June 28 at 4:30 AM
seekingalpha.com logoFDA grants orphan drug status to Kymera blood cancer drug KT-253
seekingalpha.com - June 22 at 2:16 PM
finance.yahoo.com logoKymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
finance.yahoo.com - June 22 at 9:16 AM
benzinga.com logoBoard Member at Kymera Therapeutics Acquires Company Stock Options Worth 12,000 Shares
benzinga.com - June 21 at 1:20 PM
Get Kymera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.



KYMR Media Mentions By Week

KYMR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

KYMR
News Sentiment

1.23

0.76

Average
Medical
News Sentiment

KYMR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

KYMR Articles
This Week

1

2

KYMR Articles
Average Week

Get Kymera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:KYMR) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -